Nonetheless, both CD2+ and CD34+ immunophenotypes are associated with leukocytosis, so differences in clinical outcomes between patients with CD2+ APL and CD2− APL or CD34+ APL and CD34− APL may be due to WBC counts and not because of CD2+ or CD34+ expression. The gene discussed is CD2; the disease is acute promyelocytic leukemia.